Detection of minimal residual disease in acute myeloid leukemia.
The distinction of clonogenic leukemic cells (CFU-L) and normal myeloid progenitors (GM-CFU) is a problem because both types of cells respond to the same growth factors and their clones resemble each other morphologically in culture. We investigated by means of an indirect enzyme-immunoassay the expression of "early" and "late" differentiation markers on bone marrow cell suspensions, as well as on agar clones in 18 cases of newly diagnosed acute myeloid leukemia (AML) as compared with 13 normal controls. Uncultured AML cells carried only low amounts of "late" myeloid differentiation antigen (CD15) but expressed nearly normal levels when cultured in agar with colony-stimulating factor (CSF). In contrast to normal bone marrow, AML cells were strongly reactive with "early" differentiation markers (CD10, CD20, CD34) and remained so during culture. Normal and leukemic agar clones could be specifically distinguished by CD20- and CD34 antibodies. By means of a double marker technique, it could be shown that "late" myeloid differentiation markers (CD15) and "early" markers (CD10, CD20, CD34) were coexpressed on the same cells only in AML but not in normal bone marrow. Leukemic clones were identified by phenotyping of agar clones in 17 of 19 cases investigated during complete clinical remission (CR) of the disease. A formal proof of the leukemic origin of CD20/CD34 positive clones grown in CR was made possible in four cases either by Southern blot analysis or by a cytogenetic marker. These results demonstrate that AML cells can partially differentiate in vitro in the presence of CSF. A distinction of AML from normal clones, however, is possible by their reactivity with "early" differentiation markers, because this is maintained under the differentiating influence of CSF. The technique described here identifies residual leukemic clones in the majority of AML in CR, which persist at a constant rate and increase 6 months before cytological relapse.
Medical Department III, Klinikum Grosshadern, Munich University, F.R.G.
H H
HH
Gerhartz
H
H
Schmetzer
D000362:Agar; D000906:Antibodies / Q000276:immunology; D018951:Antigens, CD20; D018952:Antigens, CD34; D000943:Antigens, Differentiation / Q000276:immunology; D000944:Antigens, Differentiation, B-Lymphocyte / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D015153:Blotting, Western; D001853:Bone Marrow / Q000276:immunology; D001854:Bone Marrow Cells; D002999:Clone Cells / Q000276:immunology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D016256:Lewis X Antigen; D015260:Neprilysin
D000906:Antibodies; D018951:Antigens, CD20; D018952:Antigens, CD34; D000943:Antigens, Differentiation; D000944:Antigens, Differentiation, B-Lymphocyte; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D016256:Lewis X Antigen; D000362:Agar; D015260:Neprilysin